Quinlan Paul T, General Counsel of Oruka Therapeutics, Inc., has reported several transactions involving the company's common stock. This filing, made on October 20, 2026, indicates a mix of share acquisitions and disposals, which may influence investor sentiment and perceptions of the company's financial health.
Background
Oruka Therapeutics, Inc. is a company based in Menlo Park, California, primarily engaged in the pharmaceutical preparations sector. The company was previously known as ARCA biopharma, Inc. and has undergone several name changes since its inception. The latest filing reflects ongoing activities within the company, which is traded under the ticker symbol ORKA.
What the Filing Says
According to the filing, Quinlan Paul T acquired 9,000 shares at a price of $7.80 each on the same day as the report. Additionally, he disposed of shares in multiple transactions, including:
- 400 shares at $74.90
- 500 shares at $76.12
- 1,000 shares at $77.21
- 4,100 shares at $78.79
- 3,000 shares at $79.49
Following these transactions, Quinlan now owns 29,995 shares of Oruka Therapeutics. The filing notes that the sales were conducted under a Rule 10b5-1 trading plan established on May 15, 2026.
Impact
This activity may affect shareholders and potential investors in Oruka Therapeutics, as insider transactions often draw attention from the market. The disclosure of these transactions may lead to increased scrutiny of the company's stock performance and trading practices, particularly in the competitive pharmaceutical preparations sector.
What's Next
The filing does not say what happens next regarding further transactions or potential changes in the company's operations.